BioSpace News Archive

International medical imaging IT and cybersecurity company Sectra has signed a contract with Niagara Health System in Canada.

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.

AlzeCure Pharma AB announced that the company has completed the clinical phase I study with repeated dosing of the drug candidate ACD856, with a focus on Alzheimer’s disease.

Aesthetic Medical International Holdings Group Limited, a leading provider of aesthetic medical services in China, announced its unaudited financial results for the first quarter ended March 31, 2022.

Oculis S.A. announced that the first patient has been enrolled in its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01, a novel, high concentration, preservative-free, topical OPTIREACH formulation of dexamethasone for the treatment of inflammation and pain following cataract surgery.

Visby Medical™, a leading medical diagnostic company, announced that it expanded its over-subscribed Series E financing round to include an additional $35 million for a total of over $135 million raised in the round.

ReCode Therapeutics announced the close of a Series B extension financing round, co-led by new investors, Leaps by Bayer, the impact investment unit of Bayer AG, AyurMaya, an affiliate of Matrix Capital Management, and with participation from Amgen Ventures.

MolecuLight Inc.announces that it has received an expansion to its FDA 510 clearance for the MolecuLight i:X® imaging device’s ability to detect the location of elevated bacterial loads in wounds.

Aileron Therapeutics announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced that Miami Cancer Institute, part of Baptist Health South Florida, has joined Caris’ Precision Oncology Alliance™.